A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly ...
A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer. A randomized phase II trial of 8 months of ...
Overall, specific lipids and amino acids were indicated as the most common metabolite classes associated with breast cancer development. However, comparison of results across studies is challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results